These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29614335)

  • 1. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Sawamukai N; Hirata S; Hanami K; Saito K; Tanaka Y
    Clin Immunol; 2018 Jun; 191():67-74. PubMed ID: 29614335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
    Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis.
    Takahashi N; Kojima T; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Hanabayashi M; Kato T; Funahashi K; Hayashi M; Tsuboi S; Kanayama Y; Sobue Y; Asai N; Matsumoto T; Watanabe T; Asai S; Ishiguro N
    Clin Rheumatol; 2019 Sep; 38(9):2451-2459. PubMed ID: 31102087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
    Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.
    Desai RJ; Varma VR; Gerhard T; Segal J; Mahesri M; Chin K; Horton DB; Kim SC; Schneeweiss S; Thambisetty M
    JAMA Netw Open; 2022 Apr; 5(4):e226567. PubMed ID: 35394510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
    Chen SK; Liao KP; Liu J; Kim SC
    Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
    Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
    PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
    Harrold LR; Reed GW; Kremer JM; Curtis JR; Solomon DH; Hochberg MC; Greenberg JD
    Ann Rheum Dis; 2015 Feb; 74(2):430-6. PubMed ID: 24297378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment.
    Nguyen MVC; Adrait A; Baillet A; Trocmé C; Gottenberg JE; Gaudin P
    Joint Bone Spine; 2019 May; 86(3):401-403. PubMed ID: 30243783
    [No Abstract]   [Full Text] [Related]  

  • 19. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.